# TherapeuticsMD, Inc.: overview TXMD · Nasdaq · CIK 25743 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/txmd.md) · [Financials](/companies/txmd/financials.md) · [Filings](/companies/txmd/filings.md) · [Insiders](/companies/txmd/insiders.md) Latest reported revenue: [$869.0k](/filings/0001213900-26-087768.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-26-087768). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [547](/filings/0001213900-25-109381.md) | [667 d](/filings/0001013762-25-003442.md) | [393](/filings/0001213900-26-055081.md) | [952](/filings/0001213900-26-087768.md) | [784](/filings/0001213900-25-109381.md) | [893 d](/filings/0001213900-26-037918.md) | [724](/filings/0001213900-26-055081.md) | [869](/filings/0001213900-26-087768.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(207.3%)](/filings/0001213900-25-109381.md) | [(97.8%) d](/filings/0001213900-26-037918.md) | [(326.0%)](/filings/0001213900-26-055081.md) | [(73.0%)](/filings/0001213900-26-087768.md) | [(109.9%)](/filings/0001213900-25-109381.md) | [(173.8%) d](/filings/0001213900-26-037918.md) | [(99.9%)](/filings/0001213900-26-055081.md) | [(93.9%)](/filings/0001213900-26-087768.md) | | Net margin | % | [(111.3%)](/filings/0001213900-25-109381.md) | [37.8% d](/filings/0001213900-26-037918.md) | [(166.2%)](/filings/0001213900-26-087768.md) | [57.9%](/filings/0001213900-26-087768.md) | [19.4%](/filings/0001213900-25-109381.md) | [(69.3%) d](/filings/0001213900-26-037918.md) | [13.1%](/filings/0001213900-26-087768.md) | [17.8%](/filings/0001213900-26-087768.md) | | Diluted EPS | $ per share | [(0.05)](/filings/0001213900-25-109381.md) | not reported | [(0.06)](/filings/0001213900-26-055081.md) | [0.05](/filings/0001213900-26-087768.md) | [0.01](/filings/0001213900-25-109381.md) | not reported | [0.01](/filings/0001213900-26-055081.md) | [0.01](/filings/0001213900-26-087768.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.6](/filings/0001564590-23-005514.md) | [70.0](/filings/0001564590-23-005514.md) | [1.3](/filings/0001013762-25-003442.md) | [1.8](/filings/0001013762-25-003442.md) | [3.0](/filings/0001213900-26-037918.md) | | Gross margin | % | [45.5%](/filings/0001564590-23-005514.md) | [98.0%](/filings/0001213900-24-028003.md) | [100.0%](/filings/0001213900-24-028003.md) | not reported | not reported | | Operating margin | % | [(3092.8%)](/filings/0001564590-23-005514.md) | [1.7%](/filings/0001213900-24-028003.md) | [(654.6%)](/filings/0001013762-25-003442.md) | [(347.1%)](/filings/0001213900-26-037918.md) | [(145.3%)](/filings/0001213900-26-037918.md) | | Net margin | % | [(6700.9%)](/filings/0001564590-23-005514.md) | [160.1%](/filings/0001213900-24-028003.md) | [(789.4%)](/filings/0001013762-25-003442.md) | [(123.9%)](/filings/0001213900-26-037918.md) | [(18.8%)](/filings/0001213900-26-037918.md) | | Diluted EPS | $ per share | [(21.66)](/filings/0001564590-23-005514.md) | [11.96](/filings/0001213900-24-028003.md) | [(0.99)](/filings/0001013762-25-003442.md) | [(0.19)](/filings/0001213900-26-037918.md) | [(0.05)](/filings/0001213900-26-037918.md) | | Free cash flow | $m | [(143)](/filings/0001564590-22-011525.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/txmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $2.6m | 1,192,191 | | Unchanged | | [Clearline Capital LP](/funds/1600136.md) | 2026-06-30 | $1.4m | 635,222 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $781.7k | 353,697 | | Unchanged | | [Tejara Capital Ltd](/funds/1879713.md) | 2026-06-30 | $761.3k | 344,482 | | Reduced −1,370 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $756.8k | 342,447 | | Added +133,237 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $324.0k | 146,599 | | Added +399 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $285.6k | 129,217 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $254.5k | 115,145 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $234.0k | 105,849 | | Reduced −3,968 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $190.3k | 86,095 | | Added +17,781 | ## Recent filings [All 983 filings](/companies/txmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:05 ET | [10-Q](/filings/0001213900-26-087768.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087768 | | 2026-08-11 | 16:00 ET | [8-K](/filings/0001213900-26-087756.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-087756 | | 2026-05-12 | 16:16 ET | [10-Q](/filings/0001213900-26-055081.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055081 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001213900-26-055070.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-055070 | | 2026-04-01 | 21:53 ET | [10-K/A](/filings/0001213900-26-037918.md) | Annual report, amended, period 2025-12-31 | 0001213900-26-037918 | | 2026-03-30 | 17:56 ET | [8-K](/filings/0001213900-26-036519.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-036519 | | 2026-03-30 | 17:43 ET | [10-K](/filings/0001213900-26-036515.md) | Annual report, period 2025-12-31 | 0001213900-26-036515 | | 2026-01-21 | 17:43 ET | [8-K](/filings/0001213900-26-005779.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001213900-26-005779 | | 2025-12-16 | 16:01 ET | [8-K](/filings/0001213900-25-122240.md) | 5.07 Shareholder vote results | 0001213900-25-122240 | | 2025-11-13 | 20:54 ET | [8-K](/filings/0001213900-25-109479.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-109479 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036515.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b1eb11f5-5599-4b6b-9cd0-6f6da80fb0dc) ## About the filer - CIK: 25743 - Tickers: TXMD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.